semaglutide and fertility ameliorates metabolic disorders in offspring via regulation of oocyte ROS of pre-pregnancy obesity mice Ozempic Babies: What You Need

10.1056/NEJMoa2312323 96 MengK.JiaH.HouX.ZhuZ.LuY.FengY.et al (2025)

91 Recent reviews that examined isoflavonoids and the health of postmenopausal women concluded that a) adding soy foods or phytoestrogens to the diet can contribute to the health of postmenopausal women, 91,101103 b) isoflavones or phytoestrogens do not increase the risk of breast, endometrial or colorectal cancer, 91,102,103 and c) the research evidence does not support classifying isoflavones as endocrine disruptors

GLP-1 receptor agonist cautions Because use of GLP-1RAs is hampered by gastrointestinal and biliary side effects, various dose escalation strategies and dietary adaptations have been implemented

Licensed pharmacological options for weight management in the UK include: Semaglutide (Wegovy, 2.4 mg weekly) a GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI 30 kg/m, or 27 kg/m with at least one weight-related comorbidity